Epibase™ In Silico for vaccine design

Lonza’s Epibase™ In Silico platform is a patented T cell epitope screening tool for the identification of potential epitopes in protein-based vaccine targets.  The tool is driven by sequence information, structural bioinformatics, and experimental data.  The Epibase™ In Silico tool predicts potential peptide/HLA binding, and HLA Class I CD8+ and CD4+ T cell epitopes.  In order to provide the optimal number of antigens that confer the broadest protection against infection, Epibase™ In Silico can identify conserved regions across several virus strains in order to help design vaccines for maximum coverage. 

The Epibase™ In Silico tool supports lead candidate selection, ranking, optimization, and rational design for the development of efficacious vaccines.

 

Help Increase Chance of Clinical Success

  • 35 HLA Class I and 85 HLA Class II allotypes are represented
  • Analysis includes binding affinity, promiscuity and frequency of allotypes
  • High accuracy of prediction based on in vitro correlations
  • Enhance immune response with in silico-guided engineering of epitope sequences
  • Can link in silico results with Epibase™ In Vitro assays for confirmation of promising vaccine candidates

 


Save Time and Money in Development

  • Lonza's scientific experts perform the work, analyze results and provide consultation on data interpretation
  • Rapidly assess vaccine candidates with a high throughput process
  • Reduce labor using in silico screening to identify top peptides as compared to in vitro screening of whole protein
  • Focus R&D resources on a smaller number of vaccine candidates with the greatest chance of success early in development